Intellectual Property Portfolio

Syntiron’s worldwide intellectual property includes over 90 issued patents and 50 pending applications covering a variety of Gram-negative and Gram-positive vaccine targets. Syntiron has the exclusive license to develop these technologies for human applications, while our sister company in the veterinary industry, Epitopix, develops the technology to improve animal health.

Issued United States patents are listed below. For a complete portfolio of worldwide intellectual property, please contact us.20130327_IssuedPatents